Earning Preview: Twist Bioscience Corp revenue is expected to increase by 26.48% this quarter, and institutional views are broadly bullish

Earnings Agent11-06

Abstract

Twist Bioscience Corp will report fiscal fourth-quarter 2026 results on November 12, 2026 Pre-Mkt; this preview summarizes consensus revenue and earnings expectations, recent margin trends, and segment dynamics including therapeutics and diagnostics, together with institutional sentiment shaping near-term stock behavior.

Market Forecast

Consensus for the current quarter points to revenue of 123.09 million US dollars, up 26.48% year-over-year, adjusted EPS of -0.369, up 13.96% year-over-year, and EBIT of -23.39 million, up 19.50% year-over-year. Formal gross margin or net margin targets for the quarter were not disclosed in the latest available materials, though commentary suggests margin resilience amid operating efficiency initiatives. Last quarter’s revenue distribution was Diagnostics 43.84 million, Therapeutics 40.41 million, Academic Research & Government 15.51 million, Global Supply Partners 12.86 million, and Industrial and Applied 5.75 million; management commentary and external previews indicate continued order flow from AI-enabled programs supporting growth across these lines. The most promising segment remains Therapeutics, delivering 40.41 million last quarter and posting recent year-over-year growth around 55% as AI-driven antibody discovery collaborations scale.

Last Quarter Review

Twist Bioscience Corp reported revenue of 118.38 million US dollars, up 23.24% year-over-year, a gross profit margin of 52.76%, a GAAP net loss attributable to the parent of -35.05 million US dollars, a net profit margin of -29.61%, and adjusted EPS of -0.56 with a year-over-year change of -19.15%. Revenue exceeded consensus by 3.89 million US dollars, while EBIT registered at -36.28 million US dollars; the company continued to invest in capacity and product capabilities while maintaining a margin profile above 50%. By business line, Diagnostics contributed 43.84 million and Therapeutics 40.41 million alongside Academic Research & Government at 15.51 million, Global Supply Partners at 12.86 million, and Industrial and Applied at 5.75 million; total revenue advanced 23.24% year-over-year.

Current Quarter Outlook

Main Business Momentum

Twist Bioscience Corp’s core revenue drivers remain anchored in sustained demand for its DNA products and solutions, with recent operating commentary highlighting order intake from AI-enabled drug discovery workflows. Management has emphasized operational throughput and acceptance rates for complex sequences, noting targets near universal acceptance across DNA products and clone genes, which supports higher conversion of designed sequences into deliverable orders. The company’s Oregon facility expansion and automation initiatives aim to underpin scale and lead-times, helping preserve a gross margin structure above 50% while serving larger, multi-arm programs. Consensus revenue of 123.09 million US dollars reflects expectations for another period of year-over-year growth as programs initiated earlier in the year progress to larger validation and characterization stages. Cost discipline continues to be a theme, with the path to adjusted EBITDA breakeven communicated throughout the year; while EBIT and EPS remain negative on consensus, both are expected to improve on a year-over-year basis. Investors will look for confirmation that production capacity and workflow efficiency can absorb rising volumes without compromising quality or turnaround, a crucial factor for sustaining margin resilience and sequential growth. The quarter’s narrative is also shaped by the company’s capital raise completed in August, which the company directed toward expanding silicon-based synthesis chip capacity, enhancing protein solutions and NGS product roadmaps, and strengthening emerging initiatives such as DNA data storage. With funding secured, execution against capacity and product priorities is the near-term determinant of whether growth and margin aspirations intersect as planned. Clarity on backlog, funnel quality, and repeat ordering from large customers will be watched closely on the call.

Most Promising Segment

Therapeutics stands out as the most promising line given recent momentum from AI/ML-enabled antibody discovery and protein engineering projects, and it contributed 40.41 million in last quarter’s revenue. Over recent quarters, year-over-year growth around 55% in therapeutics has been reported by the company, aided by cloud and platform collaborations that accelerate design-to-test cycles. The recently disclosed antibody characterization data services arrangement with Eli Lilly’s TuneLab platform reinforces demand validation from tier-one biopharma, and its scope aligns with Twist’s high-throughput capability to turn computational designs into empirical data at scale. In parallel, selection by Anthropic as an independent wet-lab evaluator for multi-arm protein design projects speaks to the company’s ability to scale experimental throughput and deliver data rapidly for AI model iteration. The partnership with Amazon’s BioDiscovery program similarly integrates Twist’s execution layer into cloud-based design environments, broadening the addressable base of computationally generated sequences that progress to lab validation. The underlying dynamic is that cloud and AI partnerships can convert upstream computational breadth into downstream laboratory revenue, with Twist monetizing the wet-lab bottleneck and leaning on process automation to protect turn-times and margins. For the quarter at hand, investors will assess whether therapeutics revenue maintains a robust trajectory from last quarter’s base while avoiding over-reliance on unusually large orders. Key datapoints include breadth of customer accounts, repeat project cadence, and time-to-decision conversion rates in antibody discovery. Upside risk comes from new program starts or scale expansions across existing collaborations; downside risk would be delays in sample handoffs, lower acceptance rates for complex constructs, or any bottleneck affecting batch throughput. The tone of guidance and commentary around win rates, backlog coverage for the next two to three quarters, and program concentration will frame the medium-term trajectory for this segment.

Key Stock Price Drivers

Near-term stock price reaction hinges on three elements: the revenue print versus 123.09 million US dollars consensus, the adjusted EPS result relative to -0.369, and the margin narrative. A revenue beat of meaningful magnitude combined with signs of margin stability or improvement could catalyze positive price action, whereas a miss on top line with weaker-than-expected commentary on margins would likely pressure shares. Investors will also parse management’s language around adjusted EBITDA breakeven progress in fiscal fourth quarter 2026, the degree of cost leverage realized in COGS and operating expenses, and where additional efficiency gains may come in fiscal 2027. Program-level disclosures—especially around therapeutics and antibody characterization—may be as consequential as consolidated metrics. Any update quantifying the size of ongoing AI-driven orders, expansion of scopes, or a deeper integration with cloud AI ecosystems could strengthen the medium-term growth narrative. Conversely, evidence of timing slippage or normalization of unusually large orders could temper near-term optimism even if headline numbers align with expectations. The capital markets calendar has also featured a Form 144 notice of proposed securities sale, which investors may consider in context of the August capital raise and liquidity; transparent commentary around capital allocation and capacity milestones can mitigate uncertainty and limit valuation volatility. Pre-earnings trading has been choppy, reflecting increased capital competition amid rising expectations; the degree to which management confirms demand trends and medium-term capacity readiness will influence whether that volatility resolves to the upside. A concrete framework for fiscal first-half 2027 growth drivers, segment mix, and margin targets—if offered—would further anchor consensus modeling and reduce dispersion. Net-net, the balance of price drivers skews toward the company’s ability to demonstrate consistent execution under higher volumes, maintain turnaround speed and acceptance rates, and convert platform collaborations into recurring, diversified revenue streams.

Analyst Opinions

Bullish opinions outweigh cautious views in recent coverage and market commentary, with approximately three-quarters of the assembled insights taking a constructive stance on revenue growth, margin resilience, and the trajectory toward improved earnings quality. Aggregated ratings data point to an overweight average rating with a mean price target of 150.33 US dollars, reflecting positive institutional sentiment despite neutral stances from select individual houses earlier in the season. Preview analyses highlight consensus expectations of 123.09 million US dollars in quarterly revenue and adjusted EPS of -0.369, with the majority framing the setup as favorable on volume growth and operating efficiency, and expecting year-over-year improvements in both EBIT and adjusted EPS. The bullish case emphasizes the confluence of demand catalysts—large AI-driven protein and antibody projects, deepening cloud collaborations, and the new services engagement with Lilly’s TuneLab—that support sustained order intake across therapeutics and related offerings. Analysts point to the >50% gross margin level achieved in recent quarters as evidence that process automation and scale are translating into structural margin durability, a prerequisite for closing the gap to adjusted EBITDA breakeven. The capital program funded in August is seen as strategically aligned with near-term demand: capacity additions for silicon-based synthesis chips, enrichment of protein solutions and NGS product pipelines, and targeted investments in emerging initiatives together position the company to handle rising sequence complexity and throughput without material deterioration in margin or turn-times. In addition to topline growth, the majority view sees incremental operating leverage as volumes climb, helping narrow losses even if EPS remains negative this quarter. Positive signals would include a revenue beat versus 123.09 million US dollars, commentary indicating incoming quarter backlog coverage, tighter cycle times from design to data delivery, and indications of repeat expansion across key accounts. On the margin front, investors will look for confirmation that product and mix shifts—particularly higher-value therapeutics work—do not materially drag gross margin, and that cost management in SG&A and R&D is consistent with the breakeven roadmap communicated throughout the year. Bullish assessments also underline the portfolio balance between diagnostics and therapeutics, with diagnostics providing a stable revenue base and therapeutics offering higher growth optionality. The constructive stance views the company’s role in cloud-AI ecosystems as a secular anchor for demand, enabling sustained scale in sequence synthesis and protein characterization. Given the recent volatility into earnings, positive institutions expect the stock’s reaction path to be most sensitive to evidence of repeatability and scale: breadth of customers supported, conversion of computational designs to accepted wet-lab sequences, and steady or improving margins under higher throughput, rather than one-off large orders alone. Overall, the majority opinion anticipates that the quarter will validate consensus expectations and reinforce the operational narrative: meaningful year-over-year revenue growth, improving earnings dynamics, and progress markers consistent with capacity expansion plans. Confirmation of this trajectory—coupled with precise detail on backlog, acceptance rates, and collaboration-sourced pipelines—would support the constructive institutional stance reflected in the overweight average rating and the 150.33 US dollars mean target, keeping attention on execution and margin preservation as the company exits fiscal 2026 and frames fiscal 2027.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment